Skip to main content
. Author manuscript; available in PMC: 2022 Jul 27.
Published in final edited form as: J Am Coll Cardiol. 2021 Nov 2;78(18):1817–1830. doi: 10.1016/j.jacc.2021.08.051

FIGURE 4. ANGPTL-3 Protein Inhibition Enhanced Remnant Lipoprotein Clearance.

FIGURE 4

ANGPTL3 inhibition unblocks the inhibitory effect of ANGPTL3 on both lipases, promoting VLDL remodeling and removal of VLDL remnants from the circulation by hepatic remnant receptors. The effects of a fully human monoclonal antibody, evinacumab, are depicted. By enhancing clearance of VLDL remnants, the pool for LDL is reduced resulting in a reduction in LDL cholesterol. ApoA5 lowers triglycerides by suppressing ANGPTL3/8-mediated LPL inhibition. Lowering of apo3 concentrations is another potential mechanism for the increased LPL activity with ANGPTL3 inhibition. FCS = familial chylomicronemia syndrome; MCS = multifactorial chylomicronemia syndrome; other abbreviations as in Figure 1.